India, Feb. 20 -- Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that reprogrammes a patient's own immune cells to fight the disease after it was recommended for NHS use. Lisocabtagene maraleucel - also called liso-cel or Breyanzi and made by Bristol Myers Squibb - has been given the green light by the National Institute for Health and Care Excellence.

The type of Car T-cell therapy involves taking a patient's T-cells and modifying them in a laboratory to target and kill cancer cells. The engineered cells are then put back into the patient's body as a one-off personalised treatment. It has been recommended for patients with large B-cell lymphoma - a fast-growing cancer that ...